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Drug Therapy In Rheumatoid Arthritis
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C S Lau, MD, MRCP(UK), FHKAM (Medicine)
Summary
Rheumatoid arthritis is such a debilitating illness that much effort has been made to find the ideal therapeutic regimen
that has a high efficacy but low toxicity rate. Although such regimen has not been found yet, judicious use of what are
currently available can improve the outcome of many of our patients. (HK Pract 1996; 18: 353-358)
Introduction
Rheumatoid arthritis (RA) is a
chronic inflammatory and potentially
deforming polyarthropathy. In
addition to functional disability, extra-
articular manifestations, though less
commonly seen in Chinese patients,1
are associated with increased
morbidity and mortality. A good drug
therapy regimen should aim to relieve
symptoms, restore functional ability
and be devoid of side effects. This,
together with help from other
disciplines such as physiotherapy,
occupational therapy and surgery,
will lead to an improvement in the
patient's quality of life.
A definite diagnosis is needed for
any treatment regimen to be effective.
The American Rheumatism Association
has a revised version of criteria for the
classification of RA (Table 1).2
Typically, there is symmetrical
polyarthritis which waxes and wanes.
Patients complain of early morning
stiffness, swelling, warmth and
redness of the affected joints. Any
joint can be affected but the
proximal interphalangeal joints,
metacarpophalangeal joints,
metartarsophalangeal joints, knees,
ankles, elbows and shoulders are
commonly involved. Rheumatoid
factor (RF) is only present in about
80% of patients. Radiologically, there
may be narrowing of joint space,
periarticular osteoporosis and bony
erosion. However, these findings may
be absent in early disease.
Table 1: The American Rheumatism Association 1987 revised criteria for
the classification of rheumatoid arthritis
* Address for correspondence: Dr M Y Mok, Medical Officer, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
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Drug treatment
rheumatoid arthritis
of
Non-steroidal anti-inflammatory
drugs (NSAIDs) are widely prescribed
to alleviate the symptoms of RA.
However, they do not alter the course
of disease. Rather, there is a group of
slow acting agents that is now
recognised to alter the progression
of the disease. They have individual
heterogenous actions which include
antibacterial, antimetabolic and
immunomodulatory effects. But their
exact mechanism of actions as a
disease modifying asent is not known.
They are collectively called disease
modifying anti-rheumatic drugs
(DMARDs), and they differ from
NSAIDs by their slow onset of action,
ability to alter the course of the
disease and their relatively higher
toxicity rate. Drugs such as non-NSAID
analgesics and tricyclic anti-
depressants also have a role in
symptom control although, as with
NSAIDs, they have no disease
modifying effects.
Choice of NSAIDs
NSAIDs act by inhibiting
cyclooxygenase (CO), an enzyme that
catalyzes the synthesis of pro-
inflammatory prostaglandins from
arachidonic acid. This enzyme is
inhibited to a varying extent by each
individual agent. However, there is
no correlation between the degree
of CO inhibition and clinical efficacy.
Also, there is an individual patient
response to different NSAIDs. The
choice of NSAID would, therefore,
only matter in terms of the frequency
of the oral preparation that is
governed by the bioavailability and
half life of the drug and the
avoidance of use of certain classes
of drug in patient groups with higher
susceptibility to their toxicity. The
selection of NSAID should be based
on the clinician's experience and the
patient's preference.3 The dosages of
commonly used NSAIDs are illustrated
in Table 2.
Table 2: Commonly used non-steroidal anti-inflammatory agents
NSAID
Naphthylkanones
Nabumetone (Relifex)
Carboxylic acids
Acetylsalicylic acid (Aspirin)
Propionic acids
Ibuprofen (Brufen)
Naproxen (Naprosyn)
Ketoprofen (Oruvail)
Acetic-acid derivatives
Indomethacin (Indocid)
Sulindac (Clinoril)
Diclofenac (Voltaren)
Fenamates
Mefenamic acid (Ponstan)
Oxicams
Piroxicam (Feldene)
Tenoxicam (Ticotil)
Gastrointestinal disturbance with
nausea and episastric discomfort is
the commonest side effect. NSAID
induced peptic ulcer may also occur
with regular Iong term treatment
especially in the elderly (>60 years).
The incidence may be reduced by
taking misoprostol, a prostaglandin
analogue, concomitantly.4 H2
antagonists have not been shown to
prevent NSAID related gastric ulcers
but they can help to heal these ulcers
more rapidly once they occur.4 The
role of co-administration of antacid
is not yet defined. Indeed, antacids
may mask dyspeptic symptoms and
delay diagnosis.
More potent inhibitors of CO are
associated with higher risks of
anaphylaxis in atopic patients.
Nonacetylated salicylates such as
propionic acids e.g. ibuprofen, can
be considered in these patients as
they are relatively weak inhibitors of
CO. Because of the effect of NSAIDs
on decreasing synthesis of
prostaglandin which plays a
protective function on the kidney, the
resulting vasoconstriction may lead to
usual dosage
500 ms bid
2-6 gm/day in 4 divided doses
400-800 mg tid
250-500 mg bid
100-200 mg bid
25-50 mg tid or qid
200 mg bid
50-75 mg bid
250 mg qid
10-20 mg bid
20 mg qd
renal ischaemia. The risk of renal
impairment increases in patients with
other risk factors like uncompensated
consestive heart failure, liver cirrhosis
and ascites.4
Combination use of NSAIDs should
be avoided as this greatly increases
toxicity without much increase in
efficacy.
When to use DMARDs?
The classical management of RA
takes the form of a therapeutic
pyramid startins with NSAIDs as the
initial therapy followed by DMARDs
with increasing efficacy and toxicity
as the pyramid ascends. There is,
however, a recent trend of using
DMARDs early in the course of RA
and using more asgressive agents in
rapidly progressive disease. This hit
hard and early regimen aims to
prevent development of bony
erosion and hence deformity, which
has been shown by radiological study
to occur during the early course of
disease.5
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Because of the higher rate of
toxicity of DMARDs, they should be
used in patients who are likely to
benefit from them so that a low risk/
benefit ratio can be achieved. The
overall drop out rate is about 40% at
2 years, mainly due to lack of efficacy
or side effects. Therefore, these
drugs should only be used in patients
who are likely to benefit from these
agents.6 They include those who
possess markers of active disease or
poor prognostic factors (Table 3).
As DMARDs are slow acting,
impatient switching to another agent
should be avoided. Most DMARDs
take at least three months to become
effective. In cases of resistant disease
that have failed to respond to high
ef f icacy DMARDs, combination
therapy can be tried although there
is so far no demonstrable increase in
efficacy over single agents.7 These
patients should better be referred to
rheumatologists for management and
monitoring of possible additive side
effects.
Choice of DMARDs
There is no evidence to suggest
any DMARD is superior to others in
terms of efficacy. Therefore, as with
NSAIDs, the choice of DMARDs is
often based on the physician's
experience of the drug tailored by
individual circumstances such as
disease presentation and co-
morbidity.8 (Table 4) summarizes
the side effects of commonly used
DMARDs.
Hydroxychloroquine(HCQ)
This antimalarial agent has modest
efficacy as a disease modifying agent
in RA. It is usually used in mild or
ol igoart icular disease. The
maintanence dosage is 200 mg per
day. Prolonged use may give rise to
a 'bull's eye' retinopathy and referral
to ophthalmologist for baseline
assessment and regular check up is
recommended.
Sulphasdlazine
This sulphonamide agent is also
commonly used in early RA. The
starting dose is 500 mg per day to be
gradually stepped up every week by
500 mg until a daily dose of 2 to
2.5 gram is reached.
Auranofin
This oral gold preparation is less
popularly used nowadays. This is
mainly due to the slow onset of action
of about 6 to 9 months and the
relatively high rate of side effects
including nausea, abdominal pain and
diarrhoea although thrombo-
cytopenia and proteinuria are less
commonly encountered compared to
injectable gold. Loose bowel motion
may improve with the use of bulk
forming agents. A total dose of
6 mg is usually used per day.
Intramuscular myocrisin
This parenteral form of gold salts
gives faster onset of action than its
oral counterpart. A test dose of
20 mg to exclude anaphylaxis is
usually given followed by 40 mg per
week until a total accumulated dose
of 500 mg is reached. The dose
interval can then be extended to
fortnightly. Further spacing out to 4
weekly can be made when a total
dose of 1 gm is reached.
Exacerbation of RA can be managed
by re-induction therapy by increasing
the dosage interval to weekly
administration.
Penillamine
This medication is less commonly
used nowadays because of
proportionately higher incidence of
side effects. The usual dosage is 750 mg
per day.
Methotrexate (MTX)
MTX is an ant i fo late agent.
However, its exact mechanism on RA
is not known. It is increasingly used
nowadays because of its high efficacy
and short onset of action. Radiological
studies have suggested true
regression of RA following MTX
treatment.9 MTX takes about 6 weeks
for its effect to be demonstrated
clinically.
Table 3: Indications for disease modifying anti-rheumatic drugs
Indication
1. Persistently 6 or more tender or swollen joints
2. Duration of morning stiffness over 45 minutes
3. High serum levels of acute phase reactants (CRP >1 mg/dl and ESR >30 mm/hr)
4. High titre of RF at presentation
5. Early radiological demonstration of bony erosion
6. Presence of extra-articular manifestations.
(Continued on page 357)
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Table 4: Side effects of disease modifying anti-rheumatic drugs
DMARDs
Hydroxychloroquine
Sulphasalazine
Oral and parenteral gold
Penicillamine
Methotrexate
Azathioprine
Cyclophosphamide
Side effects
Retinopathy, myopathy
Nausea, vomiting, haemolytic anaemia,
bone marrow suppression,
hepatotoxicity, azospermia
Nausea and diarrhoea, skin rash, oral ulcer,
bone marrow suppression,
hepatotoxicity, nephrotic syndrome
Skin rash, oral ulcer, taste disturbance,
drug induced lupus, myasthenia gravis,
Goodpasture's syndrome,
nephrotic syndrome
Bone marrow suppression, hepatotoxicity,
pneumonitis
Bone marrow suppression, hepatotoxicity,
higher incidence of malignancy, infection
Bone marrow suppression,
haemorrhagic cystitis,
higher incidence of malignancy,infection
Regular monitoring
Regular ophthalmology check up
Full blood count;liver function test
Full blood count; liver function test-
urine for protein
Full blood count; urine for proteinuria
Pretreatment hepatitis B and C status
check is desirable; full blood
count; liver function test
Full blood count, liver function test
Full blood count
Properly used, MTX has a low
toxici ty ra te . Nevertheless,
precaution is needed to prevent
potentially serious adverse effects
such as hepatotoxicity, bone marrow
suppression and pneumonitis. The
Subcomittee on Hepatic Toxicity and
Methotrexate of the American College
of Rheumatology has suggested
guidelines to identify patients who
would be at risk of MTX therapy.10 A
preliminary screening for chronic
hepatitis B and C infection is essential
before starting the drug. Although
the presence of any of these chronic
viral hepatitis is not an absolute
contraindication to the use of MTX, a
baseline liver biopsy may need to
be considered and subsequent
judicious monitoring of the liver
function is mandatory. Patients
should avoid alcohol use during
MTX treatment. MTX should be
withheld if there is an elevation of
liver enzymes to thrice its baseline
level and re-introduced at a lower
dose after the enzyme level has
returned to normal.
MTX is usually started at 2.5 mg
per week and stepped up by
2.5 mg per week till a dosage of
7.5 to 10mg is reached. A higher
dose can be used but folic acid
supplement, administered on days
between MTX treatment, is
recommended.11
Azathioprine
This is a cytotoxic agent which is
usually used later in the course of
disease, mainly because of its higher
toxicity rate. It is usually given at
50 mg or 100 mg per day.
Concomitant use with allopurinol
should be avoided as the toxicity
would be enhanced.
Cyclophosphamide
This is an alkylating agent and, like
azathioprine, is only used in resistant
cases. Patients should take plenty of
fluid to reduce the incidence of
haemorrhagic cystitis.
Cyclosporin
This is an immunomodulator
which is also used late in the disease
because of its unfavourable side
effects, narrow therapeutic margin
and high cost. Cyclosporin use
should be limited to those familiar
with this medication.
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Role of steroid in rheumatoid
arthritis
The exact mechanism of steroid
as an anti- inflammatory agent in
rheumatic diseases is not known.
Opinions vary on its use in RA. In
general, Ions term use should be
discouraged. Some consider a low
dose of oral steroid can help in the
suppression of symptoms of
inflammation and even disease
progression. However, others would
only consider low dose oral steroid
or intramuscular depot steroid as
bridging therapy for DMARDs before
they take their effect. The use of long
term steroid agents is mainly limited by
their long list of side effects.12
Intra-articular steroid is commonly
given locally to achieve a quicker
symptomatic relief. The triamcinolone
hexacetonide preparation has an
advantage over hydrocortisone or
acetonide preparation because of its
low solubility that gives longer lasting
local pain relief. Repeated steroid
injections (>3) into the same joint are
discouraged due to their potential
adverse effects on the cartilage.
How to assess the
response to medical
therapy?
The American College of
Rheumatology and the European
League Against Rheumatism have set
criteria for the assessment of activity
and outcome of RA which can be
used as guidelines in the monitoring
of response of disease to drug
therapy (Table 5).13 Any single
parameter would not be good
enough indicator of response of
disease and an overall assessment is
needed. In clinical practise, a
positive response should include
improvement in both the patient's
symptomatology and function as well
as laboratory parameters of disease
activity. •
Table 5: European League Against Rheumatism recommended criteria for
assessment of RA activity and outcome
1- :number of swollen joints
2. number of tender joints
:3. patient's global assessment score
,4. Clinician's global assessment score
5, acute; phase response
: 6. functional assessment
;7. radiological assessment
standardization
with or without joint effusion
pain on pressure or movement of
joint
a five point score, graded: 1-
asymptomatic, 2-mild, 3-
moderate, 4-severe, 5-very
severe
same as above
ESR (mm/hr), CRP (s/I)
self administered questionnaries
e.g. Health Assessment
Questionnaire
X-ray damage measured by the
Larsen or the Sharp method
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